PROCTER & GAMBLE HEALTH | NEULAND LABS | PROCTER & GAMBLE HEALTH/ NEULAND LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.7 | 28.3 | 122.5% | View Chart |
P/BV | x | 10.6 | 9.0 | 117.2% | View Chart |
Dividend Yield | % | 2.0 | 0.1 | 1,403.3% |
PROCTER & GAMBLE HEALTH NEULAND LABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
NEULAND LABS Mar-23 |
PROCTER & GAMBLE HEALTH/ NEULAND LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 2,004 | 267.7% | |
Low | Rs | 3,883 | 966 | 402.0% | |
Sales per share (Unadj.) | Rs | 740.7 | 928.4 | 79.8% | |
Earnings per share (Unadj.) | Rs | 138.2 | 127.4 | 108.5% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 168.6 | 92.0% | |
Dividends per share (Unadj.) | Rs | 95.00 | 10.00 | 950.0% | |
Avg Dividend yield | % | 2.1 | 0.7 | 305.1% | |
Book value per share (Unadj.) | Rs | 447.6 | 774.8 | 57.8% | |
Shares outstanding (eoy) | m | 16.60 | 12.83 | 129.4% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 1.6 | 390.3% | |
Avg P/E ratio | x | 33.5 | 11.7 | 287.1% | |
P/CF ratio (eoy) | x | 29.8 | 8.8 | 338.3% | |
Price / Book Value ratio | x | 10.3 | 1.9 | 539.0% | |
Dividend payout | % | 68.7 | 7.8 | 875.9% | |
Avg Mkt Cap | Rs m | 76,761 | 19,052 | 402.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 2,018 | 102.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 11,912 | 103.2% | |
Other income | Rs m | 184 | 97 | 188.7% | |
Total revenues | Rs m | 12,480 | 12,009 | 103.9% | |
Gross profit | Rs m | 3,247 | 2,718 | 119.4% | |
Depreciation | Rs m | 281 | 528 | 53.2% | |
Interest | Rs m | 8 | 131 | 5.9% | |
Profit before tax | Rs m | 3,142 | 2,157 | 145.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 522 | 162.2% | |
Profit after tax | Rs m | 2,295 | 1,635 | 140.3% | |
Gross profit margin | % | 26.4 | 22.8 | 115.7% | |
Effective tax rate | % | 27.0 | 24.2 | 111.4% | |
Net profit margin | % | 18.7 | 13.7 | 135.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 7,609 | 153.9% | |
Current liabilities | Rs m | 6,791 | 4,390 | 154.7% | |
Net working cap to sales | % | 40.0 | 27.0 | 148.1% | |
Current ratio | x | 1.7 | 1.7 | 99.5% | |
Inventory Days | Days | 263 | 6 | 4,129.3% | |
Debtors Days | Days | 343 | 1,109 | 31.0% | |
Net fixed assets | Rs m | 10,617 | 8,189 | 129.7% | |
Share capital | Rs m | 166 | 129 | 128.7% | |
"Free" reserves | Rs m | 7,265 | 9,812 | 74.0% | |
Net worth | Rs m | 7,431 | 9,941 | 74.7% | |
Long term debt | Rs m | 0 | 742 | 0.0% | |
Total assets | Rs m | 22,330 | 15,798 | 141.3% | |
Interest coverage | x | 409.1 | 17.5 | 2,336.0% | |
Debt to equity ratio | x | 0 | 0.1 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.8 | 73.0% | |
Return on assets | % | 10.3 | 11.2 | 92.2% | |
Return on equity | % | 30.9 | 16.4 | 187.7% | |
Return on capital | % | 42.4 | 21.4 | 197.9% | |
Exports to sales | % | 0 | 73.5 | 0.0% | |
Imports to sales | % | 13.1 | 15.1 | 86.2% | |
Exports (fob) | Rs m | NA | 8,750 | 0.0% | |
Imports (cif) | Rs m | 1,605 | 1,804 | 89.0% | |
Fx inflow | Rs m | 1,465 | 8,750 | 16.7% | |
Fx outflow | Rs m | 1,605 | 1,804 | 89.0% | |
Net fx | Rs m | -140 | 6,946 | -2.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 2,372 | 99.5% | |
From Investments | Rs m | -215 | -615 | 35.0% | |
From Financial Activity | Rs m | -985 | -1,358 | 72.5% | |
Net Cashflow | Rs m | 1,160 | 403 | 287.7% |
Indian Promoters | % | 0.0 | 32.7 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 31.4 | 63.6% | |
FIIs | % | 6.2 | 24.4 | 25.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 67.3 | 71.6% | |
Shareholders | 56,778 | 28,616 | 198.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA ZYDUS LIFESCIENCES DR. REDDYS LAB
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | NEULAND LABS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.13% | -1.52% | 0.52% |
1-Month | -0.85% | 8.49% | 2.62% |
1-Year | 1.04% | 235.39% | 56.25% |
3-Year CAGR | -8.66% | 41.99% | 15.24% |
5-Year CAGR | 5.03% | 57.81% | 19.65% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the NEULAND LABS share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of NEULAND LABS the stake stands at 32.7%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of NEULAND LABS.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
NEULAND LABS paid Rs 10.0, and its dividend payout ratio stood at 7.8%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of NEULAND LABS.
For a sector overview, read our pharmaceuticals sector report.
Asian shares rose cautiously on Friday as markets sobered up to the idea that U.S. rate cuts were most likely some time away.